contains approximately 5.5 ml, which is equivalent to about 100 drops (based on a standard drop size of 0.05 ml). The actual drop size may vary between 0.03 ml and 0.08 ml depending on the dropper used, but all recommendations are based on a standard size of 0.05 ml.

General Use:

Take 3–5 drops, 1 to 2 times daily.

For more specific use cases:

• Maintenance & overall wellness: 2–4 drops per day
• More aggressive fat-loss support: 5 drops, taken twice daily

For consistent results, measure drops carefully and gently shake the bottle before each use to ensure the contents are evenly mixed.

Yes. triGLP is so clean that we call it ORYGN PURE.

It’s derived from the purest salmon in the world, processed using our patented technology, and precisely refined through a controlled extraction method.

Every step — from sourcing to purification — remains in our hands so you always know exactly what you're getting.

Even our organic lemon peel and our organic ginger root follow the same strict purity standards.

Always consult your physician with medical questions, but triGLP is actuallyhypoallergenicbecause theDaltons are extremely small, making them unrecognizable to the body as proteins.  

That means your immune system does not react to triGLP.

The statements, claims, and supporting information presented on this website are based on a review of publicly available scientific literature and clinical research related to salmon-derived bioactive peptide hydrolysates.

Certain referenced human clinical studies have evaluated salmon hydrolysate ingredients at daily intake levels of approximately 4 grams, 12 grams, and 16 grams. Additional in vitro studies have demonstrated significant biological activity at lower concentrations, including approximately 1.5 grams.

ORYGN formulations are designed with consideration of these published studies, including factors such as peptide concentration, delivery format, and estimated bioavailability. However, ORYGN products themselves have not been directly evaluated in the referenced clinical trials unless explicitly stated.

Any statements regarding potential health benefits, metabolic support, or physiological effects are intended to reflect findings observed in the referenced research on similar ingredients and are not intended to represent claims that identical results will be achieved with ORYGN products. References to absorption, bioavailability, or “equivalent” intake are based on comparative formulation design assumptions and are not direct clinical equivalency claims.

Individual results may vary based on factors including diet, lifestyle, physiology, and adherence to recommended use.

These statements have not been evaluated by the Food and Drug Administration. ORYGN products are not intended to diagnose, treat, cure, or prevent any disease.

ORYGN’s triGLP™ Drops are built around a fundamentally different approach to delivering salmon-derived bioactive peptides—one that focuses on preservation, precision, and delivery rather than bulk intake.

Traditional salmon peptide products are typically processed into powders and consumed at higher daily amounts—often ranging from approximately 4 grams to 16 grams in published research. These formats rely on standard digestive breakdown, which may affect the stability and availability of key bioactive peptides.

In contrast, ORYGN’s triGLP™ Drops utilize a patented extraction process designed to help preserve the structural integrity and functional characteristics of specific peptide fractions associated with GLP-1, GLP-2, and GIP signaling pathways. These peptides are then delivered in a water-compatible liquid format intended to support efficient absorption.

This tri-pathway (GLP-1, GLP-2, and GIP) focused approach—combined with a precision extraction and delivery system—allows ORYGN to formulate a product with a smaller daily serving while being informed by the broader body of scientific research on salmon-derived peptide hydrolysates.

References to absorption, bioavailability, or “equivalent” intake are based on formulation design considerations and comparative assumptions, including insights from in vitro research demonstrating biological activity at lower concentrations (such as approximately 1.5 grams), and are not direct clinical equivalency claims. ORYGN products themselves have not been directly evaluated in the referenced clinical trials unless explicitly stated.

Individual results may vary based on factors such as metabolism, diet, and overall health.

These statements have not been evaluated by the Food and Drug Administration. ORYGN products are not intended to diagnose, treat, cure, or prevent any disease.